Neurofibroma screening: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) No edit summary |
Sara Mohsin (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}}{{S.M.}} {{SC}} | {{CMG}}; {{AE}}{{S.M.}} {{SC}} | ||
==Overview== | ==Overview== | ||
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine [[screening]] for neurofibroma. | According to the the [[United states preventive services task force recommendations scheme|U.S. Preventive Service Task Force (USPSTF)]], there is insufficient [[evidence]] to recommend routine [[screening]] for [[neurofibroma]]. | ||
==Screening== | ==Screening== | ||
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine [[screening]] for neurofibroma. | According to the the [[United states preventive services task force recommendations scheme|U.S. Preventive Service Task Force (USPSTF)]], there is insufficient [[evidence]] to recommend routine [[screening]] for [[neurofibroma]]. | ||
==References== | ==References== | ||
Latest revision as of 21:24, 27 April 2019
|
Neurofibroma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neurofibroma screening On the Web |
|
American Roentgen Ray Society Images of Neurofibroma screening |
|
Risk calculators and risk factors for Neurofibroma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]
Overview
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for neurofibroma.
Screening
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for neurofibroma.